Exagen provides preliminary Q4 and FY 2022 AVISE CTD unit volumes, Q1 2023 revenue guidance

EXAGEN INC.

2022-FY EPS reported -$2.77 revenue$45,563,000

Delivered ~33,800 AVISE CTD units in Q4 2022; ~135,000 units for full year 2022.
Expects Q1 2023 revenue between $8.2M and $9.2M.
Estimates profitability achievable at $75M annual revenue assuming 60% gross margin.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXAGEN INC. reported preliminary financial results for the three months ended December 31, 2022.

Period: the three months ended December 31, 2022
Result: preliminary results

Exact text from the filing

The Company is providing certain preliminary financial information and results of operations for the three months and year ended December 31, 2022, based on currently available information.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXAGEN INC. reported preliminary financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: preliminary results

Exact text from the filing

The Company is providing certain preliminary financial information and results of operations for the three months and year ended December 31, 2022, based on currently available information.

View on SEC.gov

Browse all earnings releases →

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-23-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.